The efficacy of anti-VEGF antibody-modified liposomes loaded with paeonol in the prevention and treatment of hypertrophic scars.
Acetophenones
/ chemistry
Administration, Cutaneous
Animals
Antibodies
/ chemistry
Biological Availability
Chemistry, Pharmaceutical
/ methods
Chondrocytes
/ drug effects
Cicatrix, Hypertrophic
/ drug therapy
Female
Gels
/ chemistry
Liposomes
/ chemistry
Male
Mice
Rabbits
Transforming Growth Factor beta1
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Box–Behnken design
Paeonol
VEGF
bevacizumab
hypertrophic scar
targeted immunoliposomes
Journal
Drug development and industrial pharmacy
ISSN: 1520-5762
Titre abrégé: Drug Dev Ind Pharm
Pays: England
ID NLM: 7802620
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
pubmed:
5
12
2018
medline:
6
6
2019
entrez:
5
12
2018
Statut:
ppublish
Résumé
The aim of this study was to investigate the efficacy of anti-VEGF antibody-modified Paeonol liposome gels (PAE-BEV-lip gels) in the prevention and treatment of hypertrophic scars (HS). Systematic optimization of the encapsulation process of anti-VEGF antibody-modified Paeonol liposomes (PAE-BEV-lips) was performed using Box-Behnken design with the optimized parameters as follows: SPC concentration of 7.36 mg mL
Identifiants
pubmed: 30512972
doi: 10.1080/03639045.2018.1546315
doi:
Substances chimiques
Acetophenones
0
Antibodies
0
Gels
0
Liposomes
0
Transforming Growth Factor beta1
0
Tumor Necrosis Factor-alpha
0
Vascular Endothelial Growth Factor A
0
paeonol
3R834EPI82
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM